Top 5 Low Price Stocks To Own For 2018

Main thesis

I believe that Tuesday Morning (NASDAQ: TUES) is a potential turnaround situation with high upside and limited downside.


According to their 10k,

We are a true closeout retailer, selling high-quality products at prices below those found in boutique, specialty and department stores. Our customers come to us for an ever-changing, exceptional assortment of brand names at great prices. Basically, they purchase items at a very low price from different sources and they sell it below retail.

What makes it interesting

Niche that is likely to be undisturbed by the ecommerce disruption right now Little debt ($30 million from accessing credit facility) with continued access to capital markets Increasing revenue despite industry headwinds, which means that the problem is likely to be internal. Insider buy in Concrete turnaround plan that could work (some of them are already working)

What I think the rest of the market missed

Only 1 analyst covering (according to yahoo finance) Niche presence in a market filled with big names Overall decrease in interest in the traditional brick and mortar retail sector Boring niche with little or no growth

Notable statistics

Top 5 Low Price Stocks To Own For 2018: Sonic Automotive Inc.(SAH)

Advisors’ Opinion:

  • [By Lee Jackson]

    These companies also reported insider buying last week: Armour Residential REIT Inc. (NYSE: ARR), Ducommun Inc. (NYSE: DCO), PJT Partners Inc. (NYSE; PJT), Sonic Automotive Inc. (NYSE: SAH)and Tandy Leather Factory Inc. (NASDAQ: TLF).

Top 5 Low Price Stocks To Own For 2018: Bayer Aktiengesellschaft (BAYZF)

Advisors’ Opinion:


    For the third quarter, the company reported cash and equivalents of $470.4 million, while net income came in at $50 million (includes a gain of $78.7 million from the Immunomedics’ warrant). Without the one-time gain, its loss of $28.7 million would still be an improvement over net loss of $31.8 million for the same quarter last year. For the fourth quarter, the company is guiding for ADCETRIS sales in the range of $82 million to $84 million (total revenue of $128 million to $130 million). In addition to the growing opportunity for ADCETRIS (peak sales in excess of $1 billion) and the intriguing prospects of tucatinib, the company has a promising pipeline of ADC candidates and immuno-oncology assets. Partnered programs with the likes of AbbVie (NYSE:ABBV), Astellas (OTCPK:ALPMY), Genmab (OTCPK:GMXAY), Bayer (OTCPK:BAYZF), Genentech and many more also lend additional credibility to the story.


    And this is pretty important ground. Hepatocellular carcinoma can be managed with local therapy (surgery, embolization, etc.), but at its most advanced stages, the options quickly start to thin out. For a decade, the only option in systemic therapy was Bayer’s (OTCPK:BAYZF) sorafenib. Recently, the effective systemic treatment armamentarium was doubled with the approval of regorafenib for second-line therapy.


    Other R&D products in Regeneron’s pipeline that we are interested in

    Fasinumab: Antibody against nerve growth factor, being developed for pain treatment like osteoarthritis. It is partnered with Teva Pharmaceutical (NASDAQ:TEVA) (for osteoarthritis, in phase 3), and is also being developed for treatment of chronic back pain. It is licensed to Mitsubishi Tanabe for the Japan territory. REGN2222: For prevention of RSV virus infection in infants, competing with Synagis from AstraZeneca (NYSE:AZN). Nesvacumab: Angiopoetin 2 antibody, being tested in combination with Eylea (in phase 2, partnered with Bayer (OTCPK:BAYZF)). Rinucumab (anti-PDGF): Being tested in treatment of wet AMD in combination with Eylea. Phase 2 trial was not successful, but the treatment duration was less (only 12 weeks versus 24 weeks for rival Ophthotech (NASDAQ:OPHT)). 28-week and 52-week data will be released later. With Ophthotech’s phase 3 failure with Fovista, we are bullish on Rinucumab’s commercial potential in wet AMD. Immuno-oncology pipeline: Checkpoint inhibitors and novel CAR-T; still in early stage.

    Click to enlarge


    Online Direct Sales – Once only consumer electronics and mobile handsets, the products it offers has grown to include 15 different categories, including home appliances and a wide array of general merchandise.

    In April, became a certified member of the American Apparel & Footwear Association (AAFA), the trusted public policy and political voice of the apparel and footwear industry, a first for a Chinese e-commerce company. In the first quarter of 2017, Avene, the leading demo-cosmetic brand for sensitive skin in European pharmacies, and three brands under Georgio Armani launched flagship stores on’s direct sales platform. JD Worldwide, a cross-border e-commerce platform set up in April 2015 to provide access to international brands (including those not available in China), has retail contracts with international brands such as Wal-Mart (NYSE:WMT), Phillips, Barcelona FC, and GNC (NYSE:GNC). Recently, it’s partnered with ASDA, a leading UK retailer under the Wal-Mart umbrella, as well as Bayer (OTCPK:BAYZF) and Cetaphil. As of March 2017, it operates 263 warehouses covering a gross floor area of 5.8 million square meters. GMV from the online direct sales business was RMB107.9 billion in the first quarter of 2017, up 42% from the first quarter of 2016. Net revenues from online direct sales increased by 40% in the first quarter of 2017 as compared to the first quarter of 2016. Fulfilled orders in the first quarter of 2017 were 477.1 million, an increase of 39% from 342.1 million in the same period in 2016. Fulfilled orders placed through mobile accounted for approximately 81% of total orders fulfilled in the first quarter of 2017, an increase of 56% compared to the same period in 2016.

    Online Marketplace – Third-party sellers offer products to customers and pay a commission to They provide transaction processing and billing services on all orders on the online marketplace and leverage their own nationwide fulfillment infrastructu


    We believe that the pharmaceutical sector has received too much negative attention. Despite the risks, a few companies offer good entry opportunities. In our previous article, we recommended Akorn. Today, we have analyzed Teva. We believe that the company is in a position to thrive in the generic market, and that it is priced very attractively. Yet, we don’t like management’s aggressive M&A strategy. We don’t like very aggressive companies since large acquisitions rarely create value for the shareholders. Contributors argue that Teva has overpaid for Actavis (its latest and largest acquisition) by at least $14B. This does not surprise us since most M&A deals are too expensive. Previous corruption issues add further doubts. Unfortunately, there is no amount of profit that can convince us to invest in a company where we do not like the management. We have sold our positions in Bayer (OTCPK:BAYZF) for similar reasons. We like Bayer, but we have sold our shares because of the Bayer-Monsanto (NYSE:MON) acquisition.

Top 5 Low Price Stocks To Own For 2018: Westinghouse Air Brake Technologies Corporation(WAB)

Advisors’ Opinion:

  • [By Lee Samaha]

    On a more positive note, Flannery appears to be making ground on some key long-term objectives.

    Management feels “good” about the ability of the healthcare segment to outperform, according to Miller. Flannery claimed GE was in “active discussions” on some aviation platforms, current & lighting and distributed power, while an announcement on the divestment of transportation (rumored to be a target of Wabtec (NYSE:WAB)) is expected by the end of the second quarter. Structural cost reductions are now expected to be above the $2 billion target outlined on the investor day presentation in November 2017. Flannery outlined that he would lead the creation of a new operating system for GE based on “lean, six sigma ad agile” involving “continuous improvement and customer experience.”

    As a reminder, GE has promised $20 billion of asset sales, and the commentary on the earnings call was reassuring, particularly as the first deal (healthcare IT assets) was underwhelming.


    Westinghouse Air Brake Technologies Corporation (WAB) scores highly based on my Warren Buffett-based model, which is based on the book Buffettology, and also the Peter Lynch-inspired approach that uses the method outlined by Lynch in One Up on Wall Street.

  • [By Joseph Griffin]

    Mountain Pacific Investment Advisers Inc. ID cut its holdings in Wabtec Co. (NYSE:WAB) by 1.2% during the first quarter, reports. The firm owned 226,515 shares of the transportation company’s stock after selling 2,800 shares during the period. Wabtec comprises 1.9% of Mountain Pacific Investment Advisers Inc. ID’s investment portfolio, making the stock its 25th biggest position. Mountain Pacific Investment Advisers Inc. ID’s holdings in Wabtec were worth $18,438,000 at the end of the most recent quarter.

  • [By Matthew DiLallo]

    Westinghouse Air Brake Technologies(NYSE:WAB), or Wabtec, is off to a solid start in 2018. The rail products company reported double-digit gains in revenue and earnings thanks to a combination of factors. As a result, the company remains on pace to hit its full-year guidance.

Top 5 Low Price Stocks To Own For 2018: Antares Pharma, Inc.(ATRS)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Friday, healthcare shares fell 0.32 percent. Meanwhile, top losers in the sector included Antares Pharma Inc (NASDAQ: ATRS), down 38 percent, and Infinity Pharmaceuticals Inc. (NASDAQ: INFI) down 16 percent.

  • [By Logan Wallace]

    BidaskClub upgraded shares of Antares Pharma (NASDAQ:ATRS) from a buy rating to a strong-buy rating in a research note issued to investors on Tuesday morning.

Top 5 Low Price Stocks To Own For 2018: Orexigen Therapeutics, Inc.(OREX)

Advisors’ Opinion:

  • [By Paul Ausick]

    Orexigen Therapeutics Inc. (NASDAQ: OREX) traded down about 12% Tuesday and posted a new 52-week low of $0.29 after closing Monday at $0.33. The stock’s 52-week high is $4.46. Volume was around 5.9 million, about 8 times the daily average. The company filed Monday for Chapter 11 bankruptcy.

  • [By Paul Ausick]

    Orexigen Therapeutics Inc. (NASDAQ: OREX) traded down about 78% Monday and posted a new 52-week low of $0.31 after closing Friday at $1.40. The stock’s 52-week high is $4.46. Volume was around 7.5million, about 15 times the daily average. The company has filed for Chapter 11 bankruptcy.

  • [By Cameron Saucier]

    Orexigen Therapeutics (Nasdaq: OREX) is a biopharmaceutical company that aims to treat obesity. The company’s flagship drug, Contrave, is approved by the Food and Drug Administration (FDA) in the United States. The drug regulates appetite, energy use, and the central nervous system. OREX rose 63% last month after it announced a new commercial and distribution agreement with Biologix FZCO. The agreement will cover 10 countries in the Middle East. OREX is currently trading at $3.30 per share and is down 79% as of Jan. 9 year over year (YOY).

  • [By Peter Graham]

    A long term chart shows Arena Pharmaceuticals along with its small capobesitytreatmentpeers EnteroMedics Inc (NASDAQ: ETRM), Orexigen Therapeutics, Inc (NASDAQ: OREX) and VIVUS, Inc (NASDAQ: VVUS) all causing severe weight loss for investor portfolios:

  • [By Keith Speights]

    Arena is out of the obesity drug business, but what about Orexigen Therapeutics (NASDAQ:OREX) or VIVUS (NASDAQ:VVUS)? The problem is that they’re both too dependent on their respective obesity drugs, Contrave and Qsymia. Neither of the drugs have performed up to expectations.

Leave a Reply

Your email address will not be published. Required fields are marked *